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Abstract
Background: Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus,
we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is a promising
approach for harnessing immunity against metastatic or locally advanced unresectable pancreatic cancer (PC).
Methods: We generated autologous DCs from the peripheral blood of HLA-A2+ patients with PC. DCs were pulsed
with three distinct A2-restricted peptides: 1) human telomerase reverse transcriptase (hTERT, TERT572Y), 2)
carcinoembryonic antigen (CEA; Cap1-6D), and 3) survivin (SRV.A2). Patients received four intradermal injections of
1 × 107 peptide-pulsed DC vaccines every 2 weeks (Day 0, 14, 28, and 42). Concurrently, patients received intramuscular
administration of Poly-ICLC at 30 μg/Kg on vaccination days (i.e., day 0, 14, 28, and 42), as well as on days 3, 17, 21, 31,
37, and 45. Our key objective was to assess safety and feasibility. The effect of DC vaccination on immune response
was measured at each DC injection time point by enumerating the phenotype and function of patient T cells.
Results: Twelve patients underwent apheresis: nine patients with metastatic disease, and three patients with locally
advanced unresectable disease. Vaccines were successfully manufactured from all individuals. We found that this
treatment was well-tolerated, with the most common symptoms being fatigue and/or self-limiting flu-like symptoms.
Among the eight patients who underwent imaging on day 56, four patients experienced stable disease while four
patients had disease progression. The median overall survival was 7.7 months. One patient survived for 28 months
post leukapheresis. MHC class I –tetramer analysis before and after vaccination revealed effective generation of
antigen-specific T cells in three patients with stable disease.
Conclusion: Vaccination with peptide-pulsed DCs in combination with poly-ICLC is safe and induces a measurable
tumor specific T cell population in patients with advanced PC.
Trial registration: NCT01410968; Name of registry: clinicaltrials.gov; Date of registration: 08/04/2011).
Background
Pancreas cancer is currently the 12th most common
cancer in the USA [1], yet by 2030, it is expected to be-
come the second leading cause of cancer death [2]. Even
when the disease is diagnosed at an early stage, the prog-
nosis is dismal [1]. In metastatic disease, modern
chemotherapy regimens such as FOLFIRINOX and nab-
paclitaxel plus gemcitabine produce median survival
times of less than a year [3, 4], underscoring the urgent
need for novel therapies [5]. Despite many agents tested,
only the EGFR tyrosine kinase inhibitor erlotinib has
gained FDA approval in combination with gemcitabine
[6], based on a 2-week improvement in survival com-
pared to gemcitabine alone [7, 8].
In the current era of immunotherapy, a variety of ma-
lignancies respond to immune checkpoint inhibitors via
activating tumor-reactive T cells [9]. Yet immune
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checkpoint inhibitors are ineffective in patients with
pancreas cancer, perhaps due to the recruitment of im-
mature myeloid cells that overwhelm infiltrating T cells
[10, 11]. Vaccines, on the other hand, have the potential
to induce an immune response in this setting of “im-
mune privilege” [10]. The most advanced vaccine strat-
egy for pancreas cancer is a combination of low dose
cyclophosphamide with GVAX, composed of two irradi-
ated GM-CSF secreting allogeneic pancreas cancer cell
lines, followed by CRS-207, a live attenuated Listeria
monocytogenes that secretes mesothelin [6]. In a land-
mark phase II study, cyclophosphamide/GVAX prime
followed by CRS-207 boost improved overall survival in
metastatic pancreas cancer patients compared to cyclo-
phosphamide/GVAX alone [6]. Unfortunately, a subse-
quent phase 2b trial in third line metastatic pancreas
cancer demonstrated a lower overall survival with the
GVAX/CRS-207 combination compared to chemother-
apy (personal communication), and [12]. So far, the
promise of immunotherapy is unfulfilled in pancreas
cancer.
One method to induce the antigen-specific CD8+ T
cell responses in vivo is the use of dendritic cells (DCs)
pulsed with antigen [13–15]. DCs pulsed with peptides
derived from tumor antigens have shown promise in
preclinical models [16]. However, despite inducing the
expansion of tumor-reactive T cells in patients, clinical
efficacy in cancer patients has been limited [17–19].
Many DC-based adjuvants have been tested in their cap-
acity to activate T cells. Our preclinical studies showed
that DCs more effectively augment T cell responses
when cultured in presence of poly(I:C), a TLR3 agonist,
[20]. In this case, poly(I:C) may act through several
mechanisms including the direct activation of DCs. To
improve poly(I:C)-mediated therapy, our collaborators
developed a GMP-grade stabilized version of poly I:C
designated poly-ICLC (Hiltonol®) [21]. Poly(IC:LC) has
been evaluated in numerous clinical trials with the goal
to boost anti-tumor immunity and was safely adminis-
tered to patients [22]. Furthermore, in glioblastoma, two
studies have shown that the combination of poly(IC:LC)
and a DC-based vaccination are well-tolerated [23, 24].
Together, these data suggest that the administration of
antigen-pulsed DCs with poly(IC:LC) could expand
tumor-reactive T cells in patients with pancreatic cancer.
With the goal of developing combinatorial DC/TLR
therapies involving the expansion of tumor-reactive CD8+
T cells in patients with pancreatic cancer, this phase I
feasibility and safety study was initiated to assess the
role of this peptide-pulsed DCs/poly(IC:LC) vaccine
in HLA-A2+ patients with metastatic or unresectable
pancreatic adenocarcinoma. Autologous DCs, pre-
pared from peripheral blood monocytes, were pulsed
with three HLA-A2-restricted peptides derived from
antigens overexpressed in pancreatic cancer including
telomerase, carcinoembryonic antigen (CEA), and sur-
vivin [25–27]. The therapy was well tolerated and
induced peptide-reactive CD8+ T cells. This effort
demonstrates the first combination of antigen-pulsed
DCs and poly(IC:LC) in patients with pancreatic can-
cer, and provides a platform for future therapies.
Methods
Patient selection
Eligible patients were ≥18 years of age with histologically
or cytologically confirmed diagnosis of adenocarcinoma
of the pancreas that was metastatic, locally advanced, or
recurrent. Patients were required to have HLA-A2 posi-
tivity by serological testing Eastern Cooperative Oncol-
ogy Group performance status ≤2, expected survival
>3 months, measureable disease per RECIST 1.1, and
adequate organ function [28, 29]. Patients with clinically
significant ascites, brain metastases, or HIV were ex-
cluded from this trial.
Study design
This pilot study, with a planned sample size of 12 pa-
tients, was designed to evaluate the feasibility and the
safety of systemic administration of polyinosinic-
polycytidylic acid stabilized with polylysine and carboxy-
methylcellulose (poly(IC:LC), or Hiltonol; Oncovir,
Washington, D.C.) concurrent with active vaccination of
autologous peptide pulsed DCs in patients with ad-
vanced adenocarcinoma of the pancreas. The DC vac-
cine consisted of a pool of three aliquots of DCs pulsed
with hTERT (YLFFYRKSV) [25–27], Cap1-6D (YLS-
GADLNL) [30], or survivin (LTLGEFLKL) [31, 32] pep-
tides that were obtained from PolyPeptide Group (San
Diego, CA). The CEF control peptide pool was obtained
from AnaSpec, (cat# 61036, Fremont, CA). The CEF
control peptides are 8–12 amino acids in length, with se-
quences derived from the human Cytomegalovirus, Ep-
stein-Barr Virus and Influenza Virus. Eligible patients
underwent leukapheresis on day -35 to generate imma-
ture DCs. At day -28 DCs were cryopreserved and sub-
sequently tested according to lot release criteria. Patients
were given a combination vaccine comprised of antigen-
pulsed DCs (1 × 107 DC intradermally delivered on days
0, 14, 28, and 42) and TLR3 agonist Poly(IC:LC) (30 μg/
kg intramuscularly administered on days 0, 3, 14, 17, 21,
28, 31, 37, 42, and 45), as outlined in Fig. 1a. All patients
were premedicated with acetaminophen and diphen-
hydramine prior to injection. Comprehensive safety eval-
uations, including physical examination, vital signs, and
clinical laboratory tests (hematology, blood chemistry,
urine analysis) were performed at baseline, prior to each
vaccination, at predetermined time points between vac-
cinations, and 2 weeks after the last vaccination. Adverse
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events were assessed for severity and relationship to
treatment, and were graded according to NCI-CTCAE
version 4.0. Baseline tumor assessment was performed
within 28 days prior to day 0, and restaging assessments
were performed within 7 days of day 56. Objective
tumor response was evaluated according to RECIST cri-
teria version 1.1 [33, 34]. Blood samples were drawn for
immune monitoring before each vaccination and two
weeks after the last vaccination (days 0, 14, 28, 42, and
56). Overall survival is defined as the time from leuka-
pheresis until death. Patients were categorized by their
response (complete/partial response, stable disease, or
progression) at day 56. The study was approved by the
Institutional Review Board at MUSC, and was performed
in accordance with the Declaration of Helsinki, Good
Clinical Practice (GCP) guidelines and applicable local
regulatory requirements and laws. All patients provided
their written informed consent.
DC expansion and differentiation
Peripheral blood monocyte-derived DCs were generated
from peripheral blood monocyte (PBMCs)-by perform-
ing standard Ficoll-density centrifugation (GE Health-
care, Uppsala, Sweden) to isolate PBMCs from patient
leukapheresed materials. PBMCs were plated in serum
free AIM-V CTS media (Life Technologies, Grand Is-
land, NY) at 2–4 × 108 cells per T225 flask and allowed
to adhere for 2 h in 5% CO2. Medium was replaced with
AIM-V containing 25 ng/mL rhIL-4 (R&D Systems,
Minneapolis, MN) and 800 IU/mL rhGM-CSF (Sanofi,
Bridgewater, NJ) and cultured for 5–7 days at 37 °C, 5%
CO2. DCs were cryopreserved in 10% DMSO/5% human
albumin at 20 × 106/mL. Prior to DC administration, a
small fraction of the final DC product was used for lot
release tests, which included determining DC viability,
sterility, mycoplasma, endotoxin, and DC phenotypic
characterization. To meet the lot release criteria the
B
A
Fig. 1 Phenotypic characterization of dendritic cells. a Schematic diagram showing the different time points for vaccination and analysis. b
Dendritic cells (DCs) were prepared from each patient (see Methods). Before treatment administration the DCs were characterized using the
flurochrome-conjugated antibodies for cell surface expression of CD11c, CD86, HLA-DR, and CD14. The data was acquired using BD Accuri flow
cytometer and analyzed using FlowJo. The numerical values adjacent to the histogram represent the mean fluorescence intensity (MFI)
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samples had to be sterile and exhibit greater than 70%
viability as determined using propidium iodide (Fluka,
Switzerland). The sterility testing included determination
of fungal sterility using BacT/Alert Anaerobic and Aer-
obic bottles (Biomerieux, Durham, NC) and mycoplasma
detection using commercial kit (Lonza, Switzerland).
Endotoxin threshold was set at less than 5 EU/kg patient
weight and determined using Endosafe®-PTS™ (Charles
River Laboratories, Charleston, SC). The DC phenotypic
determination for lot-release included flow-cytometry
based determination of surface marker expression of
CD11c, HLA-DR and CD86 (>50%), and expression for
monocyte marker CD14 (<50%). All DC preparations
passed lot-release criteria and were administered to
patients.
Vaccination
On the day of vaccination, cryopreserved DCs were
thawed, washed in AIM-V media, counted, and resus-
pended to 1 × 106 cells/mL and split into three equal
batches. Each batch was pulsed separately with one of
the following HLA-A2-binding peptides for 1 h: 20 μg/
mL of the CEA altered peptide, Cap1-6D [30], 20 μg/mL
of the telomerase peptide: hTERT [25–27], or 30 μg/mL
of the survivin peptide [31, 32]. At the end of the incu-
bation period, pulsed DCs were pooled, washed and re-
suspended to 40 × 106 cells per mL in saline. 1 × 107
antigen-pulsed DCs and poly(IC:LC) were administered
to the patient as previously described. DTH reactions
were performed twice: 1) prior to vaccination and 2) be-
tween vaccination #3 and #4.
Flow cytometry
PBMCs harvested at each time-point were assayed by
flow cytometric analysis to determine the percentage of
tetramer positive T cells. Briefly, PBMCs were first
stained with fluorescent-labeled Live/Dead antibody
(BioLegend, San Diego, CA) followed by blocking with
10 μg/mL human IgG [35]. PBMCs were stained with
fluorescent-labeled peptide tetrameric-MHC complexes
(NIH Tetramer Core Facility-Emory University) specific
for the peptide epitopes used for vaccination. Additional
phenotypic markers were incorporated into the staining
methodology including the following: CD8 (RPA-T8),
CD4 (L200), FOXP3 (259D/C7), GATA-3 (L50-823),
RORγt (Q21-559), T-bet (04-46), CD44 (G44-26),
CD62L (DREG-56), CD279 (EH12.1), CD80 (L307.4),
CD86 (2331), CD14 (M5E2) and HLA-DR (G46-6) (BD
Biosciences, San Diego, CA), and CD3 (OKT-3) (BioLe-
gend, San Diego, CA). After staining the PBMC using
standard flow cytometric methodology, cells were fixed
and analyzed with a BD LSR Fortessa using BD FACS-
Diva 6 software (BD Biosciences, San Diego, CA).
Analysis was performed using FlowJo software (TreeStar
Inc, Ashland, OR).
IFNγ ELISA/ELISPOT
The ability of PBMCs from health donors or patients to
secrete IFN-γ upon recognition of specific antigen was
measured via ELISA or ELISPOT. Specifically, PBMCs
that were frozen at different time points post vaccination
were thawed and equal number of viable cells were co-
cultured overnight with T2 cells pulsed with one of the
following peptides: Cap1-6D [30], hTERT [25–27], or
survivin peptide [31, 32]. Control conditions were T2
cells without any peptide. Supernatant was harvested
after overnight co-culturing and assayed for IFN-γ by
ELISA (R&D Systems, Minneapolis, MN). Cytokine pro-
duction was considered positive when IFN-γ levels are
more than twofold higher after co-incubation with
peptide-pulsed T2 cells compared with co-incubation
with T2 cells pulsed with irrelevant antigen. Co-culture
for ELISPOT (eBioscience, San Diego, CA) was con-
ducted similarly as per manufacturer’s protocol and the
antigen reactive T cells were quantified using the spots
with the ELISPOT plate reader.
Table 1 Patient characteristics
Characteristic Study population (n = 12)






















aRadiation to pancreatic bed, with concurrent capecitabine
bExclusive of chemotherapy concurrent with radiation
Mehrotra et al. Journal of Hematology & Oncology  (2017) 10:82 Page 4 of 13
Statistical considerations
This trial was designed as a pilot study for assessing
feasibility and thus no power calculation was performed
to justify the planned sample size (n = 12). Overall sur-
vival is described using Kaplan-Meier curves. Immune
monitoring measures were compared using paired t-tests
and Wilcoxon signed rank test were used to evaluate im-
mune monitoring parameters. Alpha level was set at
0.05 for all hypothesis tests. For determining the antigen
specific T cell response, repeated measures (% positive
cells every 14 days between day 0 and day 56) were
modeled using linear regression, estimated using gener-
alized estimating equation (GEE). Time was treated as
categorical and comparisons were made relative to day
0. An exchangeable correlation was assumed.
Results
Patients and treatment
Thirteen patients were enrolled in this single center
study at MUSC. One patient (#7) developed rapidly pro-
gressive disease prior to apheresis and withdrew from
the study. The baseline characteristics of the 12 patients
that underwent apheresis are summarized in Table 1,
Prior chemotherapy regimens, DC treatment results, and
first chemotherapy after DC vaccine are outlined per pa-
tient in Table 2. Among the 12 patients who underwent
apheresis, eight patients completed the study, three pa-
tients were withdrawn between days 3 and 17 due to dis-
ease progression, and one patient was withdrawn after
day 17 to honor the patient’s request for hospice care.
Safety and tolerability
Study treatment was well tolerated by all patients. However,
some patients experienced fatigue and/or flu-like symptoms
including fever, myalgia, chills, night sweats, and/or hot
flashes. When present, flu-like symptoms generally occurred
within 24 h of poly(IC:LC) administration, and were self-
limiting. There was one treatment interruption due to an
adverse event in a patient who had treatment held on day 3
due to a grade 2 injection site reaction: this patient subse-
quently received all other scheduled injections. Treatment-
related adverse events are summarized in Table 3.
DC preparation, characterization
Autologous DCs were generated using peripheral blood
derived adherent monocytes and characterized using cell
surface expression of co-stimulatory molecules (CD80,
CD86), antigen presenting molecule (MHC class I, HLA-
Table 2 Prior chemotherapy, dc vaccine results, and first chemotherapy after dc vaccine, per patient
Patient Disease burden
at day -35
Prior chemotherapy Response at day 56 PFS (months) OS (months) First treatment after DC vaccine
1 Metastatic Gemcitabine +/- trametinib PD 3.0 5.3 None
2 Metastatic Gemcitabine
FOLFIRINOX
Not done 2.1 2.1 None




Not done 1.8 2.1 None
4 Metastatic Gemcitabine + nab-paclitaxel
Capecitabine with radiation
FOLFIRINOX
PD 3.0 6.3 ABC294640a
5 Metastatic Gemcitabine +/- ganitumab
Gemcitabine + nab-paclitaxel
SD 4.6 13.0 Gemcitabine + nab-paclitaxel
6 Metastatic FOLFIRINOX
capecitabine with radiation





Not done 1.9 1.9 None
9 Metastatic FOLFIRINOX
gemcitabine + nab-paclitaxel





SD 8.3 13.1 Gemcitabine + nab-paclitaxel
11 Metastatic FOLFIRINOX
capecitabine
SD 4.6 9.1 Gemcitabine + nab-paclitaxel
12 Metastatic Gemcitabine + nab-paclitaxel
+ ODSHb





SD 34.3 34.3 Gemcitabine + nab-paclitaxel
aABC294640 = sphingosine kinase inhibitor
bODSH = 2-O, 3-O desulfated heparin
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DR), and monocytic marker CD14. Greater than 70% of
the DC preparation expressed CD80, CD86, and HLA-
DR. As expected, the expression of CD14 was negligible
and indicated that monocytes have differentiated to DC
phenotype. On the day of treatment administration, three
distinct DC aliquots were separately pulsed with the pep-
tide for an hour and then mixed together before injecting
intra-dermally to the patients. As depicted in the study de-
sign scheme (Fig. 1a), the DC injection was followed im-
mediately with intramuscular injection of poly(IC:LC), a
toll-like receptor 3 (TLR3) ligand in order to provide a
DC maturation signal and enhance expansion of tumor
infiltrating T cells. The ability of tumor antigen-pulsed
DCs to activate and expand the tumor epitope-reactive T
cells were measured using the peripheral blood from pa-
tients that was obtained pre- and post- DC vaccination. A
representative phenotype is shown in Fig. 1b, whereas the
phenotypic analysis from all patient DCs is presented in
Table 4. DCs from five patients that gave consent for add-
itional analysis, we observed that after frozen DCs were
thawed and matured in vitro with poly(IC:LC) there was
an increase in both IL12 and IL10 secretion to variable ex-
tent by all screened patients (i.e., # 9–13), as compared to
the un-activated control DC supernatant collected over-
night (Additional file 1: Figure S1).
Anti-tumor activity and survival
Among the eight patients who completed the study, the
response at day 56 of four of the individuals was stable
disease, while the other half experienced progressive dis-
ease. Of the 12 patients who underwent apheresis, the
median progression free survival (PFS) was 3.0 months
Table 3 Treatment related adverse events
Adverse event Number of patients experiencing adverse event
Grade 1 Grade 2 Grade 3 Grade 4 Total (%)
Fatigue 5 1 0 0 6 (50)
Hypoalbuminemia 2 4 0 0 6 (50)
Hyponatremia 6 0 0 0 6 (50)
Anemia 3 1 1 0 5 (42)
Elevated transaminases 3 2 0 0 5 (42)
Fever 4 1 0 0 5 (42)
Elevated alkaline phosphatase 2 0 2 0 4 (33)
Lymphopenia 3 1 0 0 4 (33)
Injection site reaction 3 1 0 0 4 (33)
Hypocalcemia 2 1 0 0 3 (25)
Myalgia 3 0 0 0 3 (25)
Neutropenia 3 0 0 0 3 (25)
Chills 2 0 0 0 2 (17)
Flu-like symptoms 2 0 0 0 2 (17)
Leukopenia 2 0 0 0 2 (17)
Arthritis 1 0 0 0 1 (8)
Decreased BUN 1 0 0 0 1 (8)
Hypertension 0 0 1 0 1 (8)
Hot flashes 1 0 0 0 1 (8)
Hyperbilirubinemia 1 0 0 0 1 (8)
Hypercalcemia 1 0 0 0 1 (8)
Night sweats 1 0 0 0 1 (8)
Pain 1 0 0 0 1 (8)
Pain in extremity 1 0 0 0 1 (8)
Table 4 Summary of percent expression of DC phenotypic
markers (N = 13)
DC quality parameter Mean Median Range
CD14 (<25%) 4.33 0.2 (0, 29.5)
CD86 (>50%) 83.9 87.5 (60.7, 99.6)
CD11c (>50%) 97.1 99.0 (81.5, 99.6)
HLA-DR (>50%) 85.1 86.5 (71.9, 95.4)
Percent viability (>70%) 89.8 90.0 (78.9, 96.8)
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and the median overall survival (OS) was 7.7 months
(Fig. 2). Of note, one patient (#11) initiated a non-
protocol treatment prior to progression and later
died. The patient’s PFS time was censored at the time
of initiation of other treatment, but the time to death
was included in the analysis of OS. Thus, there are
11 PFS events and there are 12 OS events (Additional
file 1: Figure S2).
Peptide-pulsed autologous DC vaccination induces
epitope reactive T cells
In order to determine if the patients (5, 6, 11, 13) with
stable disease had higher frequencies of tumor antigen
reactive T cells, we used the HLA-A2-peptide tetramer
reagents to detect peptide-specific T cells in the periph-
eral blood. A comparison of pre-DC vaccination (day 0)
vs. post-DC vaccination (day 56) showed no significant
difference between the overall CD4+ T cells, CD8+ T cells,
CD19+ B cells (CD19+), and NK cell (CD16+CD56dim and
CD16+CD56bright) subsets (Fig. 3, and Additional file 1:
Figure S3). With reference to the differences in epitope re-
active CD8+ T cells for all three epitopes (i.e., survivin,
Cap-1, h-Tert) we noticed variable degree of expansion or
contraction in the peripheral blood after each vaccination
points, and no definitive correlation could be established
between tumor epitope reactive T cells (as determined by
tetramer staining) in the patients with stable disease (red
curves) and those with progression (black curves) (Fig. 4a).
We next sought to characterize if these cells secreted cyto-
kines in an antigen specific manner. We observed that
among the patients with stable disease (5, 10, 11, 13 as
shown in red) exhibited a slight increase in INF-γ upon
stimulation with specific antigen as measured by ELISPOT
(Fig. 4b), or ELISA (Fig. 4c). The T cells activated using the
CEF positive control peptide (AnaSpec, Fremont, CA)
from both patients with stable disease and a few patients
with progression (shown in black) exhibited a response,
attesting that some viral epitope reactive T cells in patients
with progression had the ability to secrete cytokine upon
antigen re-stimulation. Further, detailed analysis of cell
surface marker expression and transcription factors were
also performed to determine the phenotype of the pre-
and post- vaccinated T cells. However, we noticed that
only T-bet expression was significantly increased on day
56 post-treatment as compared to T cells obtained on day
0. No significant difference was seen in the expression of
other cell surface marker on either central memory (Tcm)
or effector memory (Tem) cells (data not shown).
Discussion
Multiple studies have shown that advanced pancreatic
cancer (PC) has poor prognosis with present treatments,
and indicate a need for continued efforts to find im-
proved therapeutic approaches. A retrospective review of
the dose, toxicity, and efficacy of second line gemcita-
bine plus nab-paclitaxel (G +Nab-P) after FOLFIRINOX
in patients with metastatic and locally advanced unre-
sectable pancreatic cancer demonstrated its modest ac-
tivity and clinical benefit in advanced pancreatic cancer
[36]. Results from another retrospective analysis study to
determine whether cytokine-induced killer (CIK) cell-
based therapy (CBT) can improve the outcomes of ad-
vanced PC appeared to imply that CBT might prolong
survival in these high-risk PC patients [37]. Thus, recent
advances that utilize targeting of immune checkpoint
pathways, in the management of gastrointestinal malig-
nancies are being also considered [38, 39].
Fig. 2 Overall and Progression-free survival. Kaplan-Meier curves show OS and PFS vs. time since leukapheresis in months
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Immunotherapy is transforming patient care and indu-
cing unprecedented response rates in patients with meta-
static melanoma and non-small cell lung cancer [40, 41].
Yet, these therapies remain largely ineffective in pancreatic
cancer patients [42–44]. It is unclear why pancreatic cancer
is poorly amenable to current immune-based therapies, but
the ability to bolster an endogenous tumor-reactive T cell
response may be critical to advance treatment outcome.
Anti-tumor immune responses can be achieved by DC
vaccines in a number of cancers, including melanoma
[45–47], hepatocellular carcinoma [48], glioblastoma
[49], castration-resistant prostate cancer [50, 51], renal
cell carcinoma [52], acute myeloid leukemia (AML)
[53], non-small cell lung cancer [54], pancreatic cancer
[55, 56], and in various infectious diseases including
hepatitis C virus [57] and HIV infection [58].
In this phase I trial, we sought to use a vaccination ap-
proach to generate CD8+ T cells in patients that could
mediate immunity against tumor antigens overexpressed
in pancreatic cancer. We vaccinated 12 HLA-A2+ pa-
tients with metastatic or advanced unresectable disease.
Our vaccination strategy was comprised of peptide-
loaded DCs in combination with a TLR3 adjuvant called
poly-IC:LC. Moreover, the autologous DCs were pulsed
with three distinct HLA-A2-restricted peptides derived
from antigens expressed in pancreatic cancer: i) human
telomerase reverse transcriptase (hTERT, TERT572Y), ii)
carcinoembryonic antigen (CEA; Cap1-6D), and iii) sur-
vivin (SRV.A2) [25–27, 30–33]. Telomerase is a ribonu-
cleoprotein that is responsible for RNAdependent
synthesis of telomeric DNA, and is expressed in more
than 90% of the pancreatic tumors. The telomerase ac-
tivity is detected in pancreatic cancer but not in benign
tumors [59]. Similarly, CEA is a cell surface glycoprotein
and was one of the first tumor antigen to be described
[60]. It is expressed in greater than 30% of pancreatic tu-
mors [61]. Further, survivin is expressed intra-cellularly
and is a member of inhibitor of apoptosis (IAP) family
of proteins that is expressed in more than 80% of pan-
creatic tumors. The expression of survivin has been
correlated with cancer cell apoptosis and in the devel-
opment of human pancreatic duct cell tumors [62, 63].
Survivin was show to express more frequently in malig-
nant tumors than in benign tumors. Given the above
Fig. 3 Characterization of the post-vaccination lymphocyte profile.
PBMC was obtained from patients post vaccination (on days 14, 28,
42, 56). Immune cells were stained using the multiple fluorochrome-
conjugated antibodies to determine the lymphocyte subsets. The data
was acquired using BD FACS Aria and analyzed using FlowJo software.
The percentages of cellular subsets are plotted against different time
points. Each patient’s data is represented by points at each time point
(blue = stable disease; black = progression) connected over time. The
green circle represents the data from long survivor patient #13. The red
circles represent the overall mean value at each time point
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Fig. 4 Quantitative and qualitative characterization of antigen specific T cell response post-vaccination. The durability of the antigen specific T cell
response after peptide pulsed DC vaccination was determined by enumerating the difference in antigen specific T cells using the PBMCs
prepared from peripheral blood drawn prior to vaccination and d56 post-vaccination. a The tetramer staining for the Cap1, Tert, and SRV shows
the T cells reactive to these epitopes in the PBMCs for various patients at different time points. Thin red lines indicate patients with stable disease;
thin black lines patients with progression. The line obtained from the data of long survivor patient has patient ID #13 marked next to it. Thick
black line indicates fitted regression model. The data was acquired using BD FACS Aria and analyzed using FlowJo software. b ELISPOT assay was
performed as detailed in the methods. The antigen specific re-stimulation with the tumor peptide epitope leading to secretion of the effector cytokine IFNγ
was determined by quantifying the differences in ELISPOT’s between PBMC from pre vaccination (d0) vs. post-vaccination (d56) samples. Overnight stimulation
of the pre-vaccination and post-vaccination PBMCs with the three tumor epitope peptides and CEF peptide pool was done. The CEF peptide stimulation served
as positive control for the assay. Subtracting the spots seen in the unstimulated well normalized the data, and IFNγ spots were plotted at baseline vs. at day 56.
Patient data is indicated by unique symbols on the plot, with red for stable disease and black for progression. Patient with long survival is indicated with black
circle around his/her symbol in all of the plots. An x= y line is included to demonstrate changes from baseline (points above the line indicate increases; points
below the line indicate decreases). c The supernatant collected after overnight re-stimulation of the pre-vaccination and post-vaccination PBMCs with the tumor
epitope peptides was used to determine the IFNγ levels (pg/ml) using ELISA. The differences in pre-vaccination and post-vaccination levels were plotted. The
PBMCs were also stimulated in parallel with the CEF peptide pool that served as positive control for the assay. Patient data is indicated by unique symbols on
the plot, with red for stable disease and black for progression. Patient with long survival is indicated with black circle around his/her symbol in all of the plots.
An x= y line is included to demonstrate changes from baseline (points above the line indicate increases; points below the line indicate decreases)
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facts we choose the above-mentioned candidate pep-
tides in our DC vaccine platform. This is the first phase
I feasibility and safety study in pancreatic cancer pa-
tients using this approach. Not only was the treatment
well tolerated, but also induced peptide-reactive CD8+
T cells in some patients. Among the eight patients who
underwent imaging (day 56 post-treatment), four pa-
tients had stable disease and four patients progressed.
The median survival was 7.7 months from date of leu-
kapheresis, comparing favorably to the median survival
of 4.2 to 4.9 months observed with second line chemo-
therapy for metastatic pancreas cancer [64]. We found
that this vaccination approach generated antigen-specific
T cells in three patients with stable disease. Although our
therapy did not potentiate the frequency of endogenous
CD4+ T cells or NK cells in the peripheral blood, it re-
mains unknown if this regimen induced immune response
in the tumor microenvironment. It is possible that DC
vaccination strategies may have limited efficacy as stand-
alone therapeutics. However, future studies that combine
DC vaccination with other strategies, such as checkpoint
modulators or T cell immunotherapy may improve the
survival of patients with pancreatic cancer.
A number of reasons why DC vaccines fail to provide
a successful antitumor response have been put forward,
e.g., previous DC trials has been attributed to the lack of
uniformity in the preparation of the DCs, maturation
strategies, the antigen used for pulsing these DCs before
injection, or even the antigen presenting efficiency [65].
The issue of DC exhaustion could also be responsible
for high maturation signals or multiple steps of matur-
ation leading to cell death of DCs [66, 67]. Thus, all
these previous experiences with DC trials (and its fail-
ures) has led to the proposal that in order to realize the
potential of DCs, it is important that multicenter phase
II/III trials should be performed after standardizing the
production of DC vaccines between centers [68]. The
ability of DC vaccination to induce diverse neo-antigen
specific T cell receptor (TCR) repertoire in terms of both
TCR-β usage and clonal composition has also been im-
plicated as one of the mechanism responsible for better
tumor control [69], and needs to be considered for fu-
ture immunomonitoring with the DC vaccine trials to
establish its advantage over other immunotherapy regi-
mens [70]. In addition, it has been suggested that strat-
egy to incorporate DC-targeting via nanoparticles and
combinatorial targeting of multiple human DC subsets
may further improve the efficacy of DC vaccination [71].
Also, increased understanding of the DC-derived exo-
somes (Dex) that harbor functional MHC-peptide com-
plexes and other immune-stimulating components [72]
could enable the designing of the novel DC strategy to
exploit Dex as anticancer agents. In future studies, it
would be worth exploring if our vaccination approach
induces neo-antigens in the tumor, which might bolster
the generation of neo-antigen specific T cells in the pa-
tient, particularly when our vaccine approach is com-
bined with checkpoint modulators.
Overall, our results herein may shed light for prospective
patient selection in future immunotherapy studies. On the
basis of the results of this phase I trial, we will continue de-
veloping more advanced clinical trials with this particular
approach. For example, we are now conducting phase I
clinical trials with our DC vaccination in HLA-A2+ patients
as well as HLA-A2- patients, as the poly(IC:LC) adjuvants
might enhance a plethora of antitumor specific T cells. The
choice of DC administration route may impact the efficacy
of vaccines. Herein, we delivered our combination therapy
via an intradermal route. In our study, intradermal adminis-
tration was feasible and well tolerated, warranting further
development with this approach. In a related trial, we deliv-
ered this combination vaccine therapy intratumorally to the
patient, in an attempt to further activate innate immune
cells as well as bolster antigen-specific T cells in the pa-
tients. As there exists a fibronectin-rich shield around pan-
creatic tumors, it is conceivable T cells do not effectively
infiltrate this malignancy. Our objective is to further define
which subgroups of patients may respond to this intratu-
moral vaccination strategy. Our approach may contribute
to further optimization of next generation DC-based vac-
cines for patients with advanced malignancies.
Conclusions
Our study concludes that tumor peptide epitope pulsed
autologus DC vaccination in combination with TLR li-
gands could be a promising approach for controlling
tumor growth in pancreatic cancer patients.
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overnight before adding poly (IC:LC) for maturation overnight. The
supernatant was collected after 16 hrs. and evaluated for cytokines
IL12 (upper panel), and IL10 (lower panel) as per the manufacturer’s
protocol. Figure S2. PFS and OS details. The raw data showing
details of progression free survival (PFS) and the median overall
survival (OS) is presented in tabular form. Figure S3. Gating scheme
for flow cytometry analysis. PBMC was obtained from patients post
vaccination and cryopreserved cells were stained using the multiple
fluorochrome-conjugated antibodies. Cells were gated based on
singlets (FSC-A vs FSC-H), size (SSC vs FSC-H), a live-dead stain (L/D),
and subsequently markers to determine specific cell phenotypes. A)
CD3+ T cells were phenotyped for CD4 and CD8. B) CD19 B cells
were identified. C) NK cells were identified based on their CD56 and
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